Evidence summaryThrombolysis for acute ischemic stroke
Under an Elsevier user license
open archive
Cited by (0)
Competition of interest: Dr Lees has received fees or expenses from Archemix, American Stroke Association, Astellas, Asubio, Bayer, Boehringer Ingelheim, Co-Axia, D-Pharm, EVER, Ferrer, GlaxoSmithKline, infill, Johnson & Johnson, Lundbeck, Merck Sharpe and Dhome, Mitsubishi, Photothera, Quintiles, Sanofi-Aventis, Servier, Solvay, Talecris, and Wyeth. Dr Hajjar has received fees or expenses from Boehringer Ingelheim, D-Pharm, European Stroke Organization, and Lundbeck.
The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.
Copyright © 2011 Published by Elsevier Inc.